Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Active not recruiting

Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer

A Phase I Clinical Study to Determine the Optimal Dose for the Safe Immune Restoration and Immune Response of Allogeneic Cell Immunotherapy (ACIT-1) in Adult Cancer Patients

Outcome
Ongoing
Phase
Phase 1 / Phase 2
Status
Active not recruiting
Study type
Interventional
Start
25 April 2017
Expected end
July 2027
Enrollment
34 participants
Sites
2
Primary outcomes
Toxicity
Sponsor type
Industry
Results posted
No
Last update
20 January 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This study evaluates four different doses of ACIT-1 for safety and for the ability to raise effective anti-cancer immune responses in patients with pancreatic and other cancers. Approximately half of the patients will have pancreatic cancer and the other half will have other cancers.

Detailed description public domain (ClinicalTrials.gov)

The immune system has an important role in helping prevent cancer by destroying early cancer cells. When cancer does develop antigen-specific immune (T) cells are still present in the blood but are either not responding or are not effective. Vaccines stimulate these T cells to respond and kill cancer cells. ACIT-1 is designed to stimulate tumour antigen-specific T cells to respond and kill cancer cells.